Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex J Brugarolas, K Lei, RL Hurley, BD Manning, JH Reiling, E Hafen, ... Genes & development 18 (23), 2893-2904, 2004 | 1700 | 2004 |
Radiation-induced cell cycle arrest compromised by p21 deficiency J Brugarolas, C Chandrasekaran, JI Gordon, D Beach, T Jacks, ... Nature 377 (6549), 552-557, 1995 | 1674 | 1995 |
mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways PK Majumder, PG Febbo, R Bikoff, R Berger, Q Xue, LM McMahon, ... Nature medicine 10 (6), 594-601, 2004 | 1142 | 2004 |
BAP1 loss defines a new class of renal cell carcinoma S Peña-Llopis, S Vega-Rubín-de-Celis, A Liao, N Leng, A Pavía-Jiménez, ... Nature genetics 44 (7), 751-759, 2012 | 1009 | 2012 |
Targeting renal cell carcinoma with a HIF-2 antagonist W Chen, H Hill, A Christie, MS Kim, E Holloman, A Pavia-Jimenez, ... Nature 539 (7627), 112-117, 2016 | 679 | 2016 |
TSC2 regulates VEGF through mTOR-dependent and-independent pathways JB Brugarolas, F Vazquez, A Reddy, WR Sellers, WG Kaelin Cancer cell 4 (2), 147-158, 2003 | 636 | 2003 |
Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation P Kapur, S Peña-Llopis, A Christie, L Zhrebker, A Pavía-Jiménez, ... The lancet oncology 14 (2), 159-167, 2013 | 491 | 2013 |
Regulation of TFEB and V‐ATPases by mTORC1 S Peña‐Llopis, S Vega‐Rubin‐de‐Celis, JC Schwartz, NC Wolff, ... The EMBO journal 30 (16), 3242-3258, 2011 | 490 | 2011 |
The complex relationship between TFEB transcription factor phosphorylation and subcellular localization R Puertollano, SM Ferguson, J Brugarolas, A Ballabio The EMBO journal 37 (11), e98804, 2018 | 427 | 2018 |
Spectrum of diverse genomic alterations define non–clear cell renal carcinoma subtypes S Durinck, EW Stawiski, A Pavía-Jiménez, Z Modrusan, P Kapur, ... Nature genetics 47 (1), 13-21, 2015 | 367 | 2015 |
Inhibition of cyclin-dependent kinase 2 by p21 is necessary for retinoblastoma protein-mediated G1 arrest after γ-irradiation J Brugarolas, K Moberg, SD Boyd, Y Taya, T Jacks, JA Lees Proceedings of the national academy of sciences 96 (3), 1002-1007, 1999 | 365 | 1999 |
Phase I dose-escalation trial of PT2385, a first-in-class hypoxia-inducible factor-2α antagonist in patients with previously treated advanced clear cell renal cell carcinoma KD Courtney, JR Infante, ET Lam, RA Figlin, BI Rini, J Brugarolas, ... Journal of Clinical Oncology 36 (9), 867-874, 2018 | 362 | 2018 |
Molecular genetics of clear-cell renal cell carcinoma J Brugarolas Journal of clinical oncology 32 (18), 1968-1976, 2014 | 348 | 2014 |
Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene‐mediated apoptosis. LD Attardi, SW Lowe, J Brugarolas, T Jacks The EMBO journal 15 (14), 3693-3701, 1996 | 339 | 1996 |
Renal-cell carcinoma--molecular pathways and therapies J Brugarolas | 327 | 2007 |
The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus NG Cost, SE Delacroix Jr, JP Sleeper, PJ Smith, RF Youssef, BF Chapin, ... European urology 59 (6), 912-918, 2011 | 235 | 2011 |
Multistep regulation of TFEB by MTORC1 S Vega-Rubin-de-Celis, S Peña-Llopis, M Konda, J Brugarolas Autophagy 13 (3), 464-472, 2017 | 208 | 2017 |
A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma S Sivanand, S Peña-Llopis, H Zhao, B Kucejova, P Spence, ... Science translational medicine 4 (137), 137ra75-137ra75, 2012 | 203 | 2012 |
State of the science: an update on renal cell carcinoma E Jonasch, PA Futreal, IJ Davis, ST Bailey, WY Kim, J Brugarolas, ... Molecular cancer research 10 (7), 859-880, 2012 | 200 | 2012 |
p21 is a critical CDK2 regulator essential for proliferation control in Rb-deficient cells J Brugarolas, RT Bronson, T Jacks The Journal of cell biology 141 (2), 503, 1998 | 194 | 1998 |